News

The deal will expand Audentes’ portfolio with the addition of Cardiogen’s lead program for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). No therapies have yet been

A BACE (beta-site APP-cleaving enzyme-1) inhibitor program will be developed and commercialized in AD. The lead molecule will be Novartis’ oral therapy CNP520 drug and additional compounds from

The company scaled up manufacturing process for Laccure Pessary product. A search has been started for a company interested in acquiring Laccure and launching the product. Laccure CEO

The European Commission (EC) has granted marketing authorization for Strensiq, which treats the bone manifestation of pediatric-onset hypophosphatasia (HPP). Alexion said HPP is a genetic and progressive metabolic

The company previously received the first part of the award in March 2015 and successfully completed part one. Part two of the Fast-Track SBIR award totals $1.4 million

SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck

UL EduNeering, a leading provider of quality and compliance training solutions for regulated industries, will educate all CDSCO inspectors and regulators with the UL e-learning modules, co-developed and

The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. PINTA 745 is a peptibody that binds myostatin and inhibits its

The clinical trial, dubbed EVEREST, will evaluate the antiviral activity, safety and pharmacokinetics of a combination regimen of Danoprevir (ASC08), a direct-acting antiviral agent and NS3/4A inhibitor, and